Zobrazeno 1 - 10
of 51
pro vyhledávání: '"Toshio Sada"'
Autor:
Kiyoshi Arai, Yuka Morikawa, Tsuyoshi Homma, Naoko Ubukata, Toshio Sada, Hiyoyuki Tsuruoka, Hirokazu Ishikawa, Makoto Mizuno, Aoki Kazumasa
Publikováno v:
European Journal of Pharmacology. 761:226-234
The present study was designed to characterize the pharmacological profile of CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist. In the radioligand-binding assay, CS-3150 inhibited (3)H-aldosterone binding to mineralocorticoid rece
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78910e98e4871ddb9a2278da4b92843b
https://doi.org/10.1016/j.ejphar.2015.06.015
https://doi.org/10.1016/j.ejphar.2015.06.015
Publikováno v:
Journal of Veterinary Medical Science. 74:1015-1022
Although some clinical studies have suggested that spironolactone (SPL), a mineralocorticoid receptor (MR) antagonist, appears to increase the blood glucose levels, experimental studies have not supported this notion. Here, we investigated the effect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cc4feed8008c6eb2b650c3db1b32e4a
https://doi.org/10.1292/jvms.12-0007
https://doi.org/10.1292/jvms.12-0007
Publikováno v:
American Journal of Physiology-Renal Physiology. 299:F792-F801
Fibrosis is the final common pathway for various tissue lesions that lead to chronic progressive organ failure, and consequently effective antifibrotic drugs are strongly desired. However, there are few animal models in which it is possible to evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3aaa40334ce401822f0a6aaed023b4fb
https://doi.org/10.1152/ajprenal.00141.2009
https://doi.org/10.1152/ajprenal.00141.2009
Publikováno v:
Journal of Cardiovascular Pharmacology. 48:135-142
The effect of olmesartan medoxomil (OLM), an angiotensin II receptor blocker (ARB), on advanced nephropathy and mortality was evaluated in Zucker Diabetic Fatty (ZDF) rats, a type 2 diabetes model. OLM was administered from 36 weeks of age, when the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b5e2c41cec720359635b62e12208d08
https://doi.org/10.1097/01.fjc.0000245241.79959.d6
https://doi.org/10.1097/01.fjc.0000245241.79959.d6
Publikováno v:
Journal of Cardiovascular Pharmacology. 46:556-562
The purpose of this study was to examine whether coadministration of olmesartan medoxomil (OLM), an AT1 subtype specific angiotensin II receptor blocker (ARB), and pravastatin (PRV), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f063f9efa3b63c17ad070a1ea36d79f5
https://doi.org/10.1097/01.fjc.0000179434.18750.28
https://doi.org/10.1097/01.fjc.0000179434.18750.28
Autor:
Toshio, Sada, Makoto, Mizuno
Publikováno v:
Folia Pharmacologica Japonica. 124:257-269
Olmesartan medoxomil is a new angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension. Olmesartan medoxomil is a pro-drug that is converted to the active metabolite olmesartan. Olmesartan does not undergo further metabolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c61abaeeb83dfc5483fb7d87b99c2a3
https://doi.org/10.1254/fpj.124.257
https://doi.org/10.1254/fpj.124.257
Publikováno v:
Hypertension Research. 25:271-278
To evaluate the efficacy of angiotensin II receptor blockers (ARBs) for use in the treatment of diabetic nephropathy, we examined the effects of olmesartan medoxomil (olmesartan), an angiotensin II type 1 (AT1) specific ARB, on the progression of nep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7494c0e218930a07e69771ccd8803fe
https://doi.org/10.1291/hypres.25.271
https://doi.org/10.1291/hypres.25.271
Autor:
Toshio Sada
Publikováno v:
Journal of The Japan Society of Electrical Machining Engineers. 32:15-18
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1743e3ec48655e5dc86f32412a326d07
https://doi.org/10.2526/jseme.32.15
https://doi.org/10.2526/jseme.32.15
Autor:
Hiroyuki Koike, Makoto Mizuno, Toshio Sada, Masahiko Yano, Masahiro Ikeda, Hiroshi Iwao, Shokei Kim, Katsuyuki Miura, Shinya Yamanaka
Publikováno v:
Hypertension Research. 20:133-142
The present study was undertaken to examine the effects of volume overload on cardiac gene expression and the possible role of angiotensin AT1 receptor in such expression. Cardiac volume overload was prepared by abdominal aortocaval shunt in rats. Ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9813fa5293ff587368854dbf683aeeac
https://doi.org/10.1291/hypres.20.133
https://doi.org/10.1291/hypres.20.133
Autor:
Kanae Suzuki, Toshio Sada, Yoshikazu Nezu, Hideki Terashima, Mikio Kato, Hideki Kobayashi, Masayuki Ebisawa
Publikováno v:
European journal of pharmacology. 734
R-268712 is a novel and specific inhibitor of activin receptor-like kinase 5 (ALK5), a transforming growth factor β (TGF-β) type I receptor. Evaluation of in vitro inhibition indicated that R-268712 is a potent and selective inhibitor of ALK5 with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c418866505a8d2469a2e796a1a829d9b
https://pubmed.ncbi.nlm.nih.gov/24726873
https://pubmed.ncbi.nlm.nih.gov/24726873